Table F-2. Breastfeeding and breast cancer: Summary of results among subgroups (KQ 2b)

| Author, Year  Study Design  Risk of Bias | Description of Breast Cancer Outcome | Subgroup Characteristics | Results: Ever Breastfed | Results: Duration of Breastfeeding |
| --- | --- | --- | --- | --- |
| Ma, 201781  Case-control  Medium | Incident in situ and invasive breast cancer, categorized by ER, PR, and HER2 status  Triple-negative: ER-, PR-, HER2-  Luminal A-like: ER+ and/or PR+ plus HER2- | Mean age (SD), range:  Cases: 47 (8.1),  22-64  Controls: 48 (8.3), 24-64  African-American Race:  Cases: 26%  Controls: 37% | Younger women (20-44 years old): OR (95% CI)a  Triple-negative: 0.75 (0.50 to 1.12)  Luminal A-like: 0.70 (0.50 to 0.99)  Older women (45-64 years old): OR (95% CI)a  Triple-negative: 0.85 (0.62 to 1.17)  Luminal A-like: 0.83 (0.67 to 1.03):  White women: OR (95% CI)a  Triple-negative: 0.97 (0.68 to 1.02)  Luminal A-like: 0.81 (0.64 to 1.02)  African-American women: OR (95% CI)a  Triple-negative: 0.67 (0.47 to 0.96)  Luminal A-like: 0.78 (0.57 to 1.06) | Younger women (20-44 years old): OR (95% CI)a  Triple-negative  <6 months: 0.93 (0.60 to 1.44)  6-11 months: 0.49 (0.27 to 0.89)  ≥12 months: 0.60 (0.35 to 1.01)  p for trend=0.02  Luminal A-like  <6 months:0.72 (0.49 to 1.05)  6-11 months: 0.68 (0.44 to 1.07)  ≥12 months: 0.68 (0.44 to 1.05)  p for trend=0.12  Older women (45-64 years old): OR (95% CI)a  Triple-negative  <6 months: 0.97 (0.67 to 1.39)  6-11 months: 0.62 (0.35 to 1.10)  ≥12 months: 0.68 (0.44 to 1.05)  p for trend=0.17  Luminal A-like  <6 months: 0.90 (0.70 to 1.16)  6-11 months: 0.84 (0.60 to 1.17)  ≥12 months: 0.71 (0.53 to 0.96)  p for trend=0.03  White women: OR (95% CI)a  Triple-negative  <6 months: 1.14 (0.78 to 1.38)  6-11 months: 0.62 (0.37 to 1.05)  ≥12 months: 0.88 (0.56 to 1.39)  p for trend=0.27 |

| Author, Year  Study Design  Risk of Bias | Description of Breast Cancer Outcome | Subgroup Characteristics | Results: Ever Breastfed | Results: Duration of Breastfeeding |
| --- | --- | --- | --- | --- |
| Ma, 201781  Case-control  Medium  (continued) |  |  |  | Luminal A-like  <6 months: 0.85 (0.66 to 1.10)  6-11 months: 0.75 (0.54 to 1.02)  ≥12 months: 0.77 (0.57 to 1.04)  p for trend=0.07  African-American women: OR (95% CI)a  Triple-negative  <6 months: 0.79 (0.52 to 1.19)  6-11 months: 0.54 (0.26 to 1.09)  ≥12 months: 0.55 (0.32 to 0.94)  p for trend=0.01  Luminal A-like  <6 months: 0.82 (0.57 to 1.18)  6-11 months: 1.06 (0.63 to 1.77)  ≥12 months: 0.57 (0.36 to 0.90)  p for trend=0.04 |
| Warner, 201391  Cohort  Medium | Invasive ER+ breast cancer | Race:  Black women: 27%  White women: 73% | NR | Among parous women: HR (95% CI)b  Black women  <6 months: 1.31 (0.96 to 1.80)  ≥6 months: 1.27 (0.90 to 1.80)  White women  <6 months: 0.76 (0.60 to 0.98)  ≥6 months: 0.90 (0.76 to 1.07) |

aConfounders adjusted for: sub-study, study site (Los Angeles, Detroit), race, reference age, education, first-degree breast cancer family history, BMI, menopausal status, hormone therapy use, lifetime recreational physical activity, alcohol intake, smoking status, age at menarche, completed pregnancies, oral contraceptive use, age at first completed pregnancy

bConfounders adjusted for: age, time, age at first birth, parity, lactation, age at menarche, menopausal status, age at menopause, first degree family history, BMI at age 18, weight change since age 18, history of benign breast disease, alcohol consumption, OC use, and Postmenopausal hormone use

BMI = body mass index; CI = confidence interval; ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; HR = hazard ratio; KQ = Key Question; NR = not reported; OR = odds ratio; PR = progesterone receptor; SD = standard deviation.